课件：甲型11的抗病毒治疗（ 30页）.ppt

后面内容直接删除就行 资料可以编辑修改使用 资料可以编辑修改使用 资料仅供参考，实际情况实际分析 * * Structure Of The Influenza A Particle The structure of the influenza A particle is shown on this slide. Influenza viruses contain eight single-stranded RNA segments. Two types of glycoprotein, NA and HA, protrude from the surface of the virus. Small amounts of the M2 ion channel protein also are inserted through the lipid bilayer of the viral membrane. The virion matrix protein M1 is thought to underlie the lipid bilayer. NS1 is only found in infected cells and is not thought to be a structural component of the virus, but small amounts of NS2 are present in purified virions. * Inhibition of both influenza A and B viruses The mechanism of action of RELENZA is via inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release. RELENZA inhibits both influenza A and B virus neuraminidases, which are viral enzymes that are essential for the release of virus from infected cells. [11] By possibly interfering with the release of progeny influenza virus from infected host cells, RELENZA may prevent infection of new host cells and halt the spread of infection in the respiratory tract. Panel A shows the action of neuraminidase in the continued replication of virions in influenza infection. The replication is blocked by neuraminidase inhibitors (Panel B), which prevent virions from being released from the surface of infected cells.Reproduced from Moscona A. N Engl J Med. 2005:353:1363-1373, with permission.  * * * * * * * 甲型H1N1流感的抗病毒治疗 天马行空官方博客：/tmxk_docin ;QQ:1318241189 流感病毒结构 RNA 片断 HA (血凝素) 使病毒黏附于细胞表面 NA (神经氨酸酶) ，使新的病毒颗粒从细胞释放 The Drug Targets 神经氨酸酶抑制剂作用机制 抑制病毒从已感染的呼吸道上皮细胞中释放 病毒耐药的产生 流感病毒复制时产生错误（突变） 如果突变未造成任何缺陷，突变株可成为新的优势株＝自发耐药 如果病毒暴露于药物，突变影响药物结合则将产生生长优势＝药物选择性耐药 当病毒量增加时，分离出耐药株的几率增加。例如儿童——为社区流感播散的主要来源。 病毒长期暴露于药物——例如：免疫抑制状态 X 抗病毒药物简介 神经氨酸酶抑制剂 (Neuraminidase Inhibitors） 奥司他韦 Oseltamivir 扎那米韦 Zanamivir M2离子通道抑制剂 (M2 Inhibitors) 金刚烷胺 Amantadine 金刚乙胺 Rimantad